ALLERGY THERAPEUTICS PLC

Earnings Release • Jan 14, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5543X

Allergy Therapeutics PLC

14 January 2014

14 January 2014

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Trading Update and Notice of Results

Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in aluminium free allergy vaccines, will announce its unaudited interim results for the period ended 31 December 2013 on 24 March 2014.

The Company is pleased to report that it expects first half revenues before milestones and rebates of approximately £29.9m (H1 2013: £26.6m), an improvement of 12%.  This double digit sales growth has been driven by the Company's improving trading performance as it continues to increase its market share in all of its main markets and supported by a foreign exchange benefit of £1.6m.

-Ends-

For further information

Allergy Therapeutics	+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer Ian Postlethwaite, Finance Director
Peel Hunt LLP	+44 (0) 20 7418 8900
James Steel Oliver Jackson
FTI Consulting	+44 (0) 207 831 3113
Simon Conway Victoria Foster Mitchell

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination.  It has a growing business achieving sales in the prior financial year of £39.3 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.  The Company is expanding its infrastructure into the Emerging Markets.

Allergy Therapeutics vaccines are aluminium free, containing instead tyrosine as a depot, Tyrosine is a natural product that is readily metabolised and eliminated from the body.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCBCGDBCBBBGSX